No new patients should start treatment with olaratumab after study shows cancer medicine does not prolong life

January 23, 2019 – Preliminary results from the ANNOUNCE study show that olaratumab in combination with doxorubicin is not more effective at prolonging the lives of patients with soft tissue cancer than doxorubicin alone. While full results from the study are awaited, EMA is recommending that no new patients should start treatment with the medicine. For patients currently being treated with olaratumab, their doctor may consider continuing treatment with the medicine … (leggi tutto)